Abstract:Introduction: Chronic limb-threatening ischemia (CLTI) is a condition characterized by peripheral arterial disease and tissue damage caused by reduced blood flow. New therapies using various cell types, such as mesenchymal stem cells (MSCs) and mononuclear cells (MNCs), have been developed for the patients unresponsive to conventional therapies. MSCs are promising because of their ability to secrete growth factors essential for vascularization, whereas MNCs contain endothelial progenitor cells that are important for blood vessel formation. However, conventional methods for isolating these cells have limitations, especially in patients with diabetes with dysfunctional cells. To overcome this problem, a culture method called quality and quantity cultured peripheral blood MNCs (MNC-QQ) was developed to efficiently produce high-quality cells from small amounts of peripheral blood. Combining MSCs with MNC-QQs has been hypothesized to enhance therapeutic outcomes. This study aimed to examine the angiogenic efficacy of MSCs with MNC-QQs in models with severe lower limb ischemia. Methods: MNC-QQ was manufactured from the peripheral blood of healthy volunteers, while human bone marrow derived MSCs were purchased. To verify the effects of the MSC and MNC-QQs combination in angiogenesis, we conducted the HUVEC tube formation assay. For in vivo experiments, we created an ischemic limb model using BALB/c nude mice. Saline, MSCs alone, and a combination of MSCs and MNC-QQs were administered intramuscularly into the ischemic limbs. Blood flow was measured over time using laser doppler, and the ischemic limbs were harvested 21 days later for HE staining and immunostaining for histological assessment. Results: In-vitro studies demonstrated increased angiogenesis when MSCs were combined with MNC-QQs compared with MSCs alone. In vivo experiments using a mouse model of severe lower limb ischemia showed that combination therapy significantly improved blood flow recovery and limb salvage compared with MSCs alone or saline treatment. Histological analysis revealed enhanced vessel density, arteriogenesis, muscle regeneration, and reduced fibrosis in the MSC + MNC-QQ group compared with those in the saline group. Although the specific interactions between MSCs and MNC-QQs have not been fully elucidated, combined therapy leverages the benefits of both cell types, resulting in improved outcomes for vascular regeneration. Conclusions: This study highlights the potential of the simultaneous transplantation of MSCs and MNC-QQs as a promising therapeutic approach for CLTI, offering sustained long-term benefits for patients.

Toward a Mouse Model of Hind Limb Ischemia to Test Therapeutic Angiogenesis.

Therapeutic Angiogenesis of Bone Marrow Mononuclear Cells (mncs) and Peripheral Blood Mncs: Transplantation for Ischemic Hindlimb

Angiogénèse Thérapeutique Par Cellules Mononucléaires (CMN) Médullaires Et Sanguines : Transplantation Pour Ischémie De Patte Postérieure

Angiogénesis Terapéutica De Extremidades Isquémicas Mediante Linfocitos Y Monocitos De Médula Ósea En Un Modelo Murino Y De Sangre Periférica Con Uso Clínico

Role of Bone Marrow Mobilization in the Angiogenesis in Ischemic Hindlimbs of Diabetic Mice

Systematic Interrogation of Angiogenesis in the Ischemic Mouse Hind Limb

Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice

Synergistic effect of ex-vivo quality and quantity cultured mononuclear cells and mesenchymal stem cell therapy in ischemic hind limb model mice

Systematic Interrogation Of Angiogenesis In The Ischemic Mouse Hind Limb Vulnerabilities And Quality Assurance

Impacts of Femoral Artery and Vein Excision Versus Femoral Artery Excision on the Hindlimb Ischemic Model in CD-1 Mice.

Transplantation Of Mesenchymal Stem Cells Enhances Angiogenesis After Ischemic Limb Injury In Mice

B16-F10 Melanoma Cells and Cell Culture Supernatant Enhance Angiogenesis in Mouse Ischemic Limb.

E-Selectin-Overexpressing Mesenchymal Stem Cell Therapy Confers Improved Reperfusion, Repair, and Regeneration in a Murine Critical Limb Ischemia Model

Human-Induced Pluripotent Stem-Cell-Derived Smooth Muscle Cells Increase Angiogenesis to Treat Hindlimb Ischemia

Bone marrow mesenchymal stem cell-derived endothelial cells increase capillary density and accelerate angiogenesis in mouse hindlimb ischemia model

Allogenic Vertebral Body Adherent Mesenchymal Stromal Cells Promote Muscle Recovery in Diabetic Mouse Model of Limb Ischemia

A Combination of Distinct Vascular Stem/Progenitor Cells for Neovascularization and Ischemic Rescue.

Angiogenic effects of cell therapy within a biomaterial scaffold in a rat hind limb ischemia model

[The therapeutic efficacy for limb ischemia by transplantation of mobilized peripheral blood cells before and after CD34+ cell depletion]

Adipose Derived Stromal Vascular Fraction and Mesenchymal Stem Cells Improve Angiogenesis in a Rat Hindlimb Ischaemia Model

Genetically Modified Human Placenta-Derived Mesenchymal Stem Cells with Fgf-2 and Pdgf-Bb Enhance Neovascularization in A Model of Hindlimb Ischemia